Ford Robert B.'s Insider Trades & SAST Disclosures
Ford Robert B.'s most recent trade in Abbott Laboratories was a trade of 31,651 Common shares without par value done at an average price of $135.9 . Disclosure was reported to the exchange on Feb. 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Ford Robert B..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.87 per share. | 28 Feb 2025 | 31,651 | 253,305 (0%) | 0% | 135.9 | 4,300,421 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 241,706 | 241,706 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 64,897 | 284,956 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.40 per share. | 05 Feb 2025 | 285,388 | 505,447 (0%) | 0% | 38.4 | 10,958,899 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 285,388 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 131.17 per share. | 05 Feb 2025 | 285,388 | 220,059 (0%) | 0% | 131.2 | 37,435,200 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.00 per share. | 12 Sep 2024 | 127,436 | 347,495 (0%) | 0% | 47 | 5,989,492 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2024 | 127,436 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 116.04 per share. | 12 Sep 2024 | 80,299 | 281,439 (0%) | 0% | 116.0 | 9,317,896 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 116.90 per share. | 12 Sep 2024 | 61,380 | 220,059 (0%) | 0% | 116.9 | 7,175,322 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2024 | 14,243 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 48.90 per share. | 12 Sep 2024 | 14,243 | 361,738 (0%) | 0% | 48.9 | 696,483 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.05 per share. | 29 Feb 2024 | 31,610 | 220,059 (0%) | 0% | 120.1 | 3,794,781 | Common shares without par value |
| Abbott Laboratories | Ford B. Robert | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 264,293 | 264,293 | - | - | Option (right to buy) | |
| Abbott Laboratories | Ford Robert B. | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 70,332 | 251,669 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.77 per share. | 28 Feb 2023 | 30,742 | 181,337 (0%) | 0% | 99.8 | 3,067,129 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 276,082 | 276,082 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 70,008 | 212,079 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 105.10 per share. | 25 Aug 2022 | 102,425 | 142,071 (0%) | 0% | 105.1 | 10,765,154 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 41.14 per share. | 25 Aug 2022 | 56,933 | 244,496 (0%) | 0% | 41.1 | 2,342,224 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 56,933 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2022 | 45,492 | 0 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.12 per share. | 25 Aug 2022 | 45,492 | 187,563 (0%) | 0% | 39.1 | 1,779,647 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Mar 2022 | 33,414 | 197,403 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Mar 2022 | 33,414 | 142,071 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.41 per share. | 28 Feb 2022 | 26,579 | 175,485 (0%) | 0% | 122.4 | 3,253,535 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 344,827 | 344,827 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 73,992 | 202,064 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Jun 2021 | 28,746 | 128,072 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Jun 2021 | 28,746 | 163,989 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.58 per share. | 26 Feb 2021 | 22,865 | 156,818 (0%) | 0% | 121.6 | 2,779,927 | Common shares without par value |
| Abbott Laboratories | Robert B. Ford | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 359,090 | 359,090 | - | - | Option (right to buy) | |
| Abbott Laboratories | Robert B. Ford | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 70,058 | 179,683 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 May 2020 | 20,918 | 135,243 (0%) | 0% | 0 | Common shares without par value | |
| Abbott Laboratories | Robert B. Ford | Director, President and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 15 May 2020 | 20,918 | 109,625 (0%) | 0% | 0 | Common shares without par value |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges